Pharmacokinetics of ibopamine in patients with renal impairment

A. Salvadeo, G. Villa, G. Bovio, F. Pocchiari, R. Pataccini, A. Longo, G. P. Ventresca

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of a single oral dose of ibopamine 100 mg were studied in 15 patients with various degrees of chronic renal impairment (CRI) and in 8 subjects with normal renal function and of comparable age, taken as a control group. Plasma total (mainly conjugated) and free epinine and urinary metabolites (total epinine, HVA and DOPAC) were measured. Both total and free epinine were detectable at the earliest sampling time (15 min) in CRI patients and in normal subjects, thus confirming the promptness of ibopamine absorption. Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients. Progressive renal impairment was associated with higher C(max,) longer t 1/2 and larger AUC∞ of total epinine, and with reduced urinary elimination of total epinine and metabolites. Statistically significant differences (p

Original languageEnglish
Pages (from-to)98-104
Number of pages7
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Issue number2
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology


Dive into the research topics of 'Pharmacokinetics of ibopamine in patients with renal impairment'. Together they form a unique fingerprint.

Cite this